Microcap Ledger Imunon, Inc. $IMNN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Lawrenceville, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 5,611,403 [10-Q 2026-08-11]
What the company doesAI summary of filing
Imunon is a clinical-stage biotechnology company developing non-viral DNA-based immunotherapies and vaccines. The company's lead program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer that has completed a Phase II clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). The company also has a COVID-19 booster vaccine candidate (IMNN-101) in clinical development. Imunon is pre-revenue and generates no revenue from product sales, instead operating as a research and development company advancing its technology platform through clinical trials and partnerships. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$7.06M | −$7.01M | $6.86M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | $14.50M | −$13.90M | $8.78M | [DEF 14A 2026-05-04] |
| FY ended Dec 2024 | — | −$18.62M | −$18.85M | $5.87M | [DEF 14A 2026-05-04] |
- Quarterly cash burn
- −$3.51M
- Cash runway Estimate
- ~5.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 14,500,685 | [10-Q 2024-11-07] |
| 2025-02-21 | 14,620,732 | [10-K 2025-02-27] |
| 2025-05-09 | 14,620,732 | [10-Q 2025-05-12] |
| 2025-08-01 | 2,192,353 | [10-Q 2025-08-05] |
| 2025-11-10 | 3,070,354 | [10-Q 2025-11-13] |
| 2026-03-30 | 3,922,764 | [10-K 2026-03-31] |
| 2026-05-11 | 4,202,118 | [10-Q 2026-05-12] |
| 2026-08-10 | 5,611,403 | [10-Q 2026-08-11] |
- Shelf registration
- S-1 filed 2025-05-30; declared effective 2025-06-13 [S-1 2025-05-30]
Listing status
Current status: 5 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-08-28. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-08-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-28] |
| 2025-07-14 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-07-14] |
| 2025-05-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-30] |
| 2025-05-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-20] |
| 2024-11-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-27] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-25 | Tardugno Michael H | grant | 7,169 | $1.41 | [4 2026-09-28] |
| 2026-09-25 | Lindborg Stacy | grant | 6,697 | $1.41 | [4 2026-09-28] |
| 2026-09-25 | Faller Douglas Vincent | grant | 4,390 | $1.41 | [4 2026-09-28] |
| 2026-09-11 | Tardugno Michael H | grant | 5,824 | $1.47 | [4 2026-09-15] |
| 2026-09-11 | Lindborg Stacy | grant | 5,504 | $1.47 | [4 2026-09-15] |
| 2026-09-11 | Faller Douglas Vincent | grant | 4,211 | $1.47 | [4 2026-09-15] |
| 2026-08-28 | Tardugno Michael H | grant | 7,371 | $1.60 | [4 2026-09-01] |
| 2026-08-28 | Lindborg Stacy | grant | 6,822 | $1.60 | [4 2026-09-01] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Material agreement entered; Unregistered sale of equity; Charter, bylaws or fiscal year change |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 8-K | Director or officer change |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Results of operations |
| 2026-06-30 | 8-K | Director or officer change |
| 2026-06-16 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-04 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-05-04 | 8-K | Director or officer change |
Alerts for $IMNN
Email me when Imunon, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.